APT成像在胶质瘤分级中的作用:系统综述与Meta分析
该系统综述与Meta分析纳入23篇以组织病理学为参考标准的研究,评估酰胺质子转移(APT)成像对胶质瘤分级的诊断价值;APT加权信号可区分低级别与高级别胶质瘤(合并AUC 0.84),并可在不同WHO分级及IDH野生型与突变型之间显示差异,但作者认为仍需更多研究优化其可靠性。
要点
- APT加权信号强度可区分低级别与高级别胶质瘤,合并AUC为0.84。
- APT可区分WHO 2级与3级、2级与4级,以及IDH野生型与突变型胶质瘤。
- 作者认为APT是有前景的无创分级工具,但需更多研究优化其可靠性。
核心结论
- APT成像在区分低级别与高级别胶质瘤方面是有前景的工具,并可能预测组织病理学分级,但作者认为仍需更多研究来优化和提高其可靠性。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Medline和Embase于2008年1月1日至2020年9月15日间发表的文献。
- 纳入23篇以组织病理学为参考标准、报道APT用于胶质瘤分级的研究。
- 采用QUADAS-2评估研究质量,采用随机效应模型标准化均数差Meta分析及ROC Meta分析的AUC评估诊断性能。
诊断标准与关键数值
- APT加权信号区分低级别与高级别胶质瘤的估计效应量为-1.61个标准差(p < 0.0001),合并AUC为0.84。
- APT加权信号区分WHO 2级与3级胶质瘤的效应量为-1.83个标准差(p = 0.005)。
- APT加权信号区分WHO 2级与4级胶质瘤的效应量为-2.34个标准差(p < 0.0001)。
- APT加权信号区分IDH野生型与IDH突变型胶质瘤的效应量为0.94个标准差(p = 0.003)。
临床应用与阅片要点
- 作者认为APT成像可作为区分低级别与高级别胶质瘤的无创工具,并可能预测组织病理学分级。
- 作者指出仍需更多研究来优化和提高APT成像的可靠性。
局限性
- 作者在结论中明确指出,仍需更多研究来优化和提高APT成像的可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Gliomas are diagnosed and staged by conventional MRI. Although non-conventional sequences such as perfusion-weighted MRI may differentiate low-grade from high-grade gliomas, they are not reliable enough yet. The latter is of paramount importance for patient management. In this regard, we aim to evaluate the role of Amide Proton Transfer (APT) imaging in grading gliomas as a non-invasive tool to provide reliable differentiation across tumour grades.
METHODS: A systematic search of PubMed, Medline and Embase was conducted to identify relevant publications between 01/01/2008 and 15/09/2020. Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) was used to assess studies' quality. A random-effects model standardized mean difference meta-analysis was performed to assess APT's ability to differentiate low-grade gliomas (LGGs) from high-grade gliomas (HGGs), WHO 2-4 grades, wild-type from mutated isocitrate dehydrogenase (IDH) gliomas, methylated from unmethylated O6-methylguanine-DNA methyltransferase (MGMT) gliomas. Area under the curve (AUC) of the Receiver Operating Characteristic (ROC) meta-analysis was employed to assess the diagnostic performance of APT.
RESULTS: 23 manuscripts met the inclusion criteria and reported the use of APT to differentiate glioma grades with histopathology as reference standard. APT-weighted signal intensity can differentiate LGGs from HGGs with an estimated size effect of (-1.61 standard deviations (SDs), p < 0.0001), grade 2 from grade 3 (-1.83 SDs, p = 0.005), grade 2 from grade 4 (-2.34 SDs, p < 0.0001) and IDH wild-type from IDH mutated (0.94 SDs, p = 0.003) gliomas. The combined AUC of 0.84 highlights the good diagnostic performance of APT-weighted imaging in differentiating LGGs from HGGs.
CONCLUSIONS: APT imaging is an exciting prospect in differentiating LGGs from HGGs and with potential to predict the histopathological grade. However, more studies are required to optimize and improve its reliability.
引用
- Sotirios B, Demetriou E, Topriceanu CC, et al. The role of APT imaging in gliomas grading: A systematic review and meta-analysis. Eur J Radiol. 2020. PMID: 33120241. doi:10.1016/j.ejrad.2020.109353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。